News Sentiment

FBIO sentiment intelligence

Fortress Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 59 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.13 Week of 31 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend inactive

-6.3% over one week, +3.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Negative

Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend inactive 3.0% over four weeks
Fair value 26.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 8
Market source 8
Seeking Alpha 5
GlobeNewswire 5
TradingView 4
Stock Titan 3
simplywall.st 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 20
Regulatory and legal 5
Analyst action 4
Guidance 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Fortress Biotech Inc (FBIO), noting its current valuation score of 7.96, which ranks 108 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is 0.85, significantly above its recent low. It also mentions that relevant d

Tone
Neutral 50/100
Event
Market update
Published
27 Jul 2026 22:39
Source
TradingKey
GlobeNewswire Direct company coverage

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics closed a $130 million Series B financing. These proceeds will support the late-stage global clinical development and commercialization preparation of dotinurad, a next-generation treatmen

Tone
Positive 70/100
Event
Market update
Published
27 Jul 2026 11:40
Source
GlobeNewswire
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Fortress Biotech Inc (FBIO) has an earnings forecast score of 8.00, ranking 55 out of 155 in the Pharmaceuticals industry. Analysts have an average price target of $10.75 for FBIO, with a significant upside of +220.70% from its current price. The company's expected revenue for th

Tone
Neutral 50/100
Event
Earnings
Published
26 Jul 2026 02:10
Source
TradingKey
TradingView Direct company coverage

FBIO Forecast — Price Target — Prediction for 2027

This article provides an overview of Fortress Biotech, Inc. (FBIO), including its stock performance, analyst price targets, and financial data. It notes a current price of 3.36 USD and a 1-year analyst price target max and min of 5.00 USD. The company's market capitalization is ‪

Tone
Positive 66/100
Event
Analyst action
Published
28 Jun 2026 18:10
Source
TradingView
TradingView Direct company coverage

Fortress Biotech, Inc. Actuals & Estimates (NASDAQ:FBIO)

This article provides an overview of Fortress Biotech, Inc. (NASDAQ: FBIO), including its recent stock performance, financial estimates, and market data. It details key financial figures, analyst forecasts, and information on the company's earnings, market capitalization, and emp

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:39
Source
TradingView
Stock Titan Direct company coverage

Fortress Biotech (NASDAQ: FBIO) reports 2026 director and auditor vote tallies

Fortress Biotech (NASDAQ: FBIO) announced the results of its 2026 annual stockholders' meeting, held virtually on June 17. Stockholders elected seven directors to serve until the 2027 meeting and ratified KPMG LLP as the independent registered public accounting firm for the year

Tone
Neutral 50/100
Event
Earnings
Published
23 Jun 2026 20:04
Source
Stock Titan
AD HOC NEWS Direct company coverage

Fortress Biotech Stock - Saturday deep dive on the business model

This article provides a deep dive into Fortress Biotech's business model, highlighting its "hub-and-spoke" structure through majority or minority-owned subsidiaries. The company acquires and develops biopharmaceutical product candidates in various therapeutic areas like oncology,

Tone
Positive 65/100
Event
Market update
Published
20 Jun 2026 18:43
Source
AD HOC NEWS
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Fortress Biotech Inc (FBIO), highlighting its current price momentum score of 8.51 and its position between resistance and support levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy/sell

Tone
Positive 67/100
Event
Market update
Published
18 Jun 2026 11:10
Source
TradingKey
Finviz Direct company coverage

FBIO - Fortress Biotech Inc Stock Price and Quote

This article provides a comprehensive overview of Fortress Biotech Inc. (FBIO) stock, including its latest financial data, performance metrics, analyst ratings, and a chronological list of recent news and corporate highlights. It details key financial figures like market cap, P/E

Tone
Positive 65/100
Event
Analyst action
Published
05 Jun 2026 01:39
Source
Finviz
GlobeNewswire Direct company coverage

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech (FBIO) reported strong first-quarter 2026 financial results, with consolidated net income attributable to common stockholders reaching $108.4 million or $3.44 per share (basic). Key drivers included the FDA approval of ZYCUBO® for Menkes disease and the subsequen

Tone
Positive 71/100
Event
Earnings
Published
13 May 2026 12:09
Source
GlobeNewswire